<DOC>
	<DOCNO>NCT02032836</DOCNO>
	<brief_summary>Administration iloprost aerosol compare two nebulizer : FOX I-Neb</brief_summary>
	<brief_title>Comparative PK PD Study PAH Patients ( Fox vs. I-Neb )</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Iloprost</mesh_term>
	<criteria>Male female age ≥ 18 year Current diagnosis pulmonary hypertension ( updated Dana Point Classification 1 ) . Current inhalative therapy 5 µg iloprost use INeb nebulizer WHO functional class III time patient 's commencement inhalative therapy iloprost Hemodynamic diagnosis Pulmonary arterial hypertension ( PAH ) show mean pulmonary arterial pressure ( mPAP ) &gt; 25 mmHg , pulmonary capillary wedge pressure ( PCWP ) leave ventricular end diastolic pressure ( LVEDP ) &lt; 15 mmHg pulmonary vascular resistance ( PVR ) &gt; 320 dyn•s•cm5 If nonspecific type chronic treatment PAH administer : Stable dosage least 4 week screen If PAHspecific drug treatment ( endothelin receptor antagonist ( ERA ) phosphodiesterase5 ( PDE5 ) inhibitor ) administer : Stable dosage least 3 month screen . PAH related etiology , especially pulmonary venoocclusive disease ( PVOD ) Clinically relevant obstructive lung disease Evidence thromboembolic disease ( probable pulmonary embolism ) within 3 year screen Cerebrovascular event within 3 month screen Atrial septostomy within 6 month screen Severe arrhythmia , severe coronary heart disease unstable angina , myocardial infarction within 6 month screen , congenital acquire valvular defect clinically relevant myocardial function disorder unrelated PAH Systolic blood pressure &lt; 85 mm Hg , uncontrolled systemic hypertension ( systolic BP &gt; 160 mmHg diastolic BP &gt; 100 mmHg ) Hepatic impairment ( Child Pugh B , C ) chronic renal insufficiency ( creatinine &gt; 2.5 mg/dl ) /or requirement dialysis Clinically relevant bleeding disorder condition increase risk hemorrhage ( active ulcer , trauma etc . ) Addition dose change PAH specific drug treatment ERA PDE5 inhibitor within 3 month screen , addition dose change nonspecific treatment PAH calcium channel blocker , nitrate , digitalis , diuretic within 4 week Screening , kind prostanoid mention inclusion criterion within less 5 halflives treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>